cagrilintide amylin analog Novo Nordisk: A long-acting, selective human insulin analog, NN1213, for weight management Combined GLP-1/amylin analog bests monotherapy

Front Behav Neurosci (2018) 12:266

Patients on GLP-1 medications who want to maximize fat metabolism and support liver function Patients with mild weight loss goals (10-20 pounds) who prefer a lighter-touch approach Anyone seeking an energy boost even without active weight loss goals Patients concerned about liver health, particularly those with fatty liver disease Patients on hormone replacement therapy optimizing body composition Patients experiencing fatigue, brain fog, or low energy Timeline for Results Most patients notice increased energy within the first 1-2 injections, often within a day or two of their first dose

However, long-term safety in humans has not been established , and risks may increase with improper sourcing, excessive dosing, or chronic use

Vasavada, A., & Sanghavi, D